^
    Back
    Association details:
    Biomarker:Chr t(2;17)(p23;q23) CLTC/ALK
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:TAE-684 (ALK inhibitor, LRRK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    PLoS One
    Title:

    Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas

    Excerpt:
    NVP-TAE684 repressed ALK-activated signalling pathways and induced apoptosis of LM1 DLBCL cells. Inhibition of ALK-activity resulted in sustained tumor regression in the xenotransplant tumor model. Molecular cytogenetics as well as RT-PCR for CLTC-ALK transcripts revealed t(2;17) (p23;q23) with expression of CLTC-ALK in the cells of the relapsed tumor (Figure 2A).
    DOI:
    10.1371/journal.pone.0018436